Chemotherapy outcomes in EGFR‐TKI resistant patients with common and uncommon EGFR mutation: An exploratory retrospective cohort study
Thoracic Cancer · 2023
DOI: 10.1111/1759-7714.14930 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Chien-Yu Lin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ROC. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Cheng Kung University Hospital.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Some prospective studies have shown that second‐generation tyrosine kinase inhibitors (TKIs) provide better control in patients with non‐small cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor ( EGFR ) mutations. However, studies comparing second‐line chemotherapy efficacy between NSCLC patients with common and uncommon EGFR mutations remain rare. This retrospective study compared treatment outcomes in these patients.
Methods
Patients with EGFR ‐mutated advanced‐stage NSCLC who received first‐line EGFR‐TKIs in a tertiary referral center were retrospectively reviewed between January 2010 and August 2022. Patients with a negative T790M test at disease progression who received second‐line chemotherapy were enrolled. We compared progression‐free (PFS) and overall (OS) survival between advanced NSCLC patients with common and uncommon EGFR mutations using Kaplan–Meier and log‐rank tests.
Results
In total, 209 (54.8%) patients had a negative T790M mutation test and received second‐line chemotherapy, of which 192 (91.8%) had a common EGFR mutation (exon 19 deletion or exon 21 L858R substitution), and 17 (8.2%) had an uncommon EGFR mutation. Patients with common EGFR mutations had significantly longer PFS than those with uncommon EGFR mutations (4.57 vs. 2.57 months, p = 0.031). A Cox proportional hazard regression analysis controlling for potential confounding factors indicated that an uncommon EGFR mutation was an independent prognostic factor for PFS.
Conclusion
This study suggests that patients with uncommon EGFR mutations have poorer chemotherapy responses and shorter survival than those with common EGFR mutations. The development of new treatment strategies for these patients remains an unmet need.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ROC.
- Department of Internal Medicine, Tainan Municipal Hospital, Tainan, Taiwan, ROC.
- Department of Medical Imaging, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ROC.
- Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ROC.
- Institute of Clinical Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ROC.
- Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ROC.
ORCID-Profile: Chien-Yu Lin, Po-Lan Su, Chien-Chung Lin
Förderung
- National Cheng Kung University Hospital
Zitieren
APA
Lin, C. Y., Hu, C. H., Hsu, C. F., Tsai, J. S., Chen, C. W., Lin, C. Y., Chang, C. C., Yen, Y. T., Tseng, Y. L., Su, P. L., & Lin, C. C. (2023). Chemotherapy outcomes in EGFR‐TKI resistant patients with common and uncommon EGFR mutation: An exploratory retrospective cohort study. Thoracic Cancer. https://doi.org/10.1111/1759-7714.14930
Vancouver
Lin CY, Hu CH, Hsu CF, Tsai JS, Chen CW, Lin CY, et al. Chemotherapy outcomes in EGFR‐TKI resistant patients with common and uncommon EGFR mutation: An exploratory retrospective cohort study. Thoracic Cancer. 2023. doi:10.1111/1759-7714.14930
BibTeX
@article{Lin2023,
author = {Lin, Chien-Yu and Hu, Chia-Hao and Hsu, Chia-Fu and Tsai, Jeng-Shiuan and Chen, Chian-Wei and Lin, Chia-Yin and Chang, Chao-Chun and Yen, Yi-Ting and Tseng, Yau-Lin and Su, Po-Lan and Lin, Chien-Chung},
title = {Chemotherapy outcomes in EGFR‐TKI resistant patients with common and uncommon EGFR mutation: An exploratory retrospective cohort study},
journal = {Thoracic Cancer},
year = {2023},
doi = {10.1111/1759-7714.14930}
}
EUVIMED